1. Medtech Insight
  2. >>Geography
  3. >>Europe

EU One Step Closer To Confirming EMA's New Pivotal Role In Device Matters

 
• By Amanda Maxwell

Industry opposes the proposed new role of European Medicines Agency in overseeing devices availability in a healthcare crisis. But a new Regulation may be adopted in March and its fallout looks set to herald a new era for device supply management and regulation.

EMA

In light of the health care product supply challenges during the current pandemic, the European Parliament and the Council of the EU have reached a provisional agreement on the European Commission’s proposed Regulation for a reinforced role for the European Medicines Agency in healthcare crises.

The document lays out the new role the EMA would play in overseeing various aspects of device management, as well...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

EU Authorities Unite In Call For Urgent Overhaul Of Medtech Regulations

 
• By Amanda Maxwell

EU member states have issued a consensus statement on the urgent need to build momentum to tackle governance and centralization issues as part of much-needed reform of the EU medtech regulatory system.

‘Eyes – A Window Into The Heart’: Retinal AI Tool Predicts Future Risk Of Heart Attack And Stroke

 
• By Natasha Barrow

A deep-learning AI-based retinal image scanning tool can predict the risk of cardiovascular events over a 10-year period with 70% accuracy. The test is comparable to routine GP health checks, researchers from the University of Dundee have shown.

Whoops! FDA Says Company Marketed Unauthorized Device. The Company Says The FDA Is Wrong

 
• By Brian Bossetta

A recent FDA warning letter claims a Boston firm that specializes in wearable technology marketed a blood pressure device without agency approval. The company rejects the assertion and says the agency is out of step with federal law.